Procedures for risk-stratification of lung cancer using Buccal Nanocytology

Biomedical Optics Express

Volumn 7, Issue 9, 2016, Pages 3795-3810

  Subramanian, H ^a,b   Viswanathan, P ^a   Cherkezyan, L ^a   Iyengar, R ^b   Rozhok, S ^b   Verleye, M ^b   Derbas, J ^b   Czarnecki, J ^a   Roy, H K ^c   Backman, V ^a  

^a Northwestern University   (United States)

^b NanoCytomics LLC   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS;

BUCCAL CELLS; CLINICAL PRACTICES; LATE STAGE; LUNG CANCER; REPEATABLE RESULTS; RISK STRATIFICATION;

DISEASES;

NANOMATERIAL;

AREA UNDER THE CURVE; ARTICLE; BUCCAL NANOCYTOLOGY; CANCER MORTALITY; CANCER STAGING; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICAL PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 84989838958     PISSN: None     EISSN: 21567085     Source Type: Journal    
DOI: 10.1364/BOE.7.003795     Document Type: Article

References (52)

1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA Cancer J. Clin. 66(1), 7-30 (2016).
2. P. B. Bach, G. A. Silvestri, M. Hanger, and J. R. Jett, “Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition),” Chest 132, 69S-77S (2007).
3. T. Neumann, M. Meyer, F. W. Patten, F. L. Johnson, Y. S. Erozan, W. J. Frable, P. K. Gupta, M. B. Zaman, and A. C. Nelson, “Premalignant and Malignant Cells in Sputum from Lung Cancer Patients,” Cancer 117(6), 473-481 (2009).
4. T. C. Kennedy, S. P. Proudfoot, W. A. Franklin, T. A. Merrick, G. Saccomanno, M. E. Corkill, D. L. Mumma, K. E. Sirgi, Y. E. Miller, P. G. Archer, and A. Prochazka, “Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories,” Cancer Res. 56(20), 4673-4678 (1996).
5. E. K. J. Risse, G. P. Vooijs, and M. A. van’t Hof, “Diagnostic Significance of “Severe Dysplasia” in Sputum Cytology,” Acta Cytol. 32(5), 629-634 (1988).
6. Y. P. Sher, J. Y. Shih, P. C. Yang, S. R. Roffler, Y. W. Chu, C. W. Wu, C. L. Yu, and K. Peck, “Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes,” Clin. Cancer Res. 11(1), 173-179 (2005).
7. C. Wu, H. Hao, L. Li, X. Zhou, Z. Guo, L. Zhang, X. Zhang, W. Zhong, H. Guo, R. M. Bremner, and P. Lin, “Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients,” J. Thorac. Oncol. 4(1), 30-36 (2009).
8. S. S. Devesa, F. Bray, A. P. Vizcaino, and D. M. Parkin, “International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising,” Int. J. Cancer 117(2), 294-299 (2005).
9. H. Welch, S. Woloshin, L. Schwartz, L. Gordis, P. Gotzsche, R. Harris, B. Kramer, and D. Ransohoff, “Overstating the Evidence for Lung Cancer Screening: The I-ELCAP Study and its News Coverage,” Arch. Intern. Med. 167(21), 2289 (2007).
10. D. A. Lieberman, J. Holub, G. Eisen, D. Kraemer, and C. D. Morris, “Utilization of colonoscopy in the United States: results from a national consortium,” Gastrointest. Endosc. 62(6), 875-883 (2005).
11. J. M. Croswell, S. G. Baker, P. M. Marcus, J. D. Clapp, and B. S. Kramer, “Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial,” Ann. Intern. Med. 152, 505-512 (2010).
12. T. R. Church, W. C. Black, D. R. Aberle, C. D. Berg, K. L. Clingan, F. Duan, R. M. Fagerstrom, I. F. Gareen, D. S. Gierada, G. C. Jones, I. Mahon, P. M. Marcus, J. D. Sicks, A. Jain, and S. Baum; National Lung Screening Trial Research Team, “Results of initial low-dose computed tomographic screening for lung cancer,” N. Engl. J. Med. 368(21), 1980-1991 (2013).
13. L. L. Humphrey, M. Deffebach, M. Pappas, C. Baumann, K. Artis, J. P. Mitchell, B. Zakher, R. Fu, and C. G. Slatore, “Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation,” Ann. Intern. Med. 159(6), 411-420 (2013).
14. K. Steiling, J. Ryan, J. S. Brody, and A. Spira, “The field of tissue injury in the lung and airway,” Cancer Prev. Res. (Phila.) 1(6), 396-403 (2008).
15. G. D. Dakubo, J. P. Jakupciak, M. A. Birch-Machin, and R. L. Parr, “Clinical implications and utility of field cancerization,” Cancer Cell Int. 7(1), 2 (2007).
16. B. J. Braakhuis, M. P. Tabor, J. A. Kummer, C. R. Leemans, and R. H. Brakenhoff, “A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications,” Cancer Res. 63(8), 1727-1730 (2003).
17. A. Spira, J. Beane, V. Shah, G. Liu, F. Schembri, X. Yang, J. Palma, and J. S. Brody, “Effects of cigarette smoke on the human airway epithelial cell transcriptome,” Proc. Natl. Acad. Sci. U.S.A. 101(27), 10143-10148 (2004).
18. A. Spira, J. E. Beane, V. Shah, K. Steiling, G. Liu, F. Schembri, S. Gilman, Y. M. Dumas, P. Calner, P. Sebastiani, S. Sridhar, J. Beamis, C. Lamb, T. Anderson, N. Gerry, J. Keane, M. E. Lenburg, and J. S. Brody, “Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer,” Nat. Med. 13(3), 361-366 (2007).
19. L. Kopelovich, D. E. Henson, A. F. Gazdar, B. Dunn, S. Srivastava, G. J. Kelloff, and P. Greenwald, “Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect,” Clin. Cancer Res. 5(12), 3899-3905 (1999).
20. D. Sidransky, “The Oral Cavity as a Molecular Mirror of Lung Carcinogenesis,” Cancer Prev. Res. (Phila.) 1(1), 12-14 (2008).
21. J. O. Boyle, Z. H. Gümüs, A. Kacker, V. L. Choksi, J. M. Bocker, X. K. Zhou, R. K. Yantiss, D. B. Hughes, B. Du, B. L. Judson, K. Subbaramaiah, and A. J. Dannenberg, “Effects of cigarette smoke on the human oral mucosal transcriptome,” Cancer Prev. Res. (Phila.) 3(3), 266-278 (2010).
22. M. Bhutani, A. K. Pathak, Y.-H. Fan, D. D. Liu, J. J. Lee, H. Tang, J. M. Kurie, R. C. Morice, E. S. Kim, W. K. Hong, and L. Mao, “Oral Epithelium as a Surrogate Tissue for Assessing Smoking-Induced Molecular Alterations in the Lungs,” Cancer Prev. Res. (Phila.) 1(1), 39-44 (2008).
23. T. Shani, A. Onn, A. Kabha, I. Ben-Dov, I. Adam, N. Amariglio, R. Yahalom, G. Rechavi, L. Trakhtenbrot, and A. Hirshberg, “Chromosomal numerical aberrations in apparently normal oral mucosa of heavy smokers affected by lung cancer,” Oral Oncol. 46(2), 96-99 (2010).
24. J. Sanz-Ortega, F. Roig, M. M. Al-Mousa, M. C. Saez, A. Muñoz, J. Sanz-Esponera, and L. Callol, “17p13 (p53 locus), 5q21 (APC locus) and 9p21 (p16 locus) allelic deletions are frequently found in oral exfoliative cytology cells from smoker patients with non-small-cell lung cancer,” Histol. Histopathol. 22(5), 541-545 (2007).
25. M. Us-Krasovec, J. Erzen, M. Zganec, M. Strojan-Flezar, J. Lavrencak, D. Garner, A. Doudkine, and B. Palcic, “Malignancy associated changes in epithelial cells of buccal mucosa: a potential cancer detection test,” Anal. Quant. Cytol. Histol. 27(5), 254-262 (2005).
26. R. A. Kemp and B. Turic, “Can early lung cancer be detected from buccal mucosal scrapings?” Chest 128(4), 154S (2005).
27. H. Subramanian, P. Pradhan, Y. Liu, I. R. Capoglu, X. Li, J. D. Rogers, A. Heifetz, D. Kunte, H. K. Roy, A. Taflove, and V. Backman, “Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells,” Proc. Natl. Acad. Sci. U.S.A. 105(51), 20118-20123 (2008).
28. H. K. Roy, C. B. Brendler, H. Subramanian, D. Zhang, C. Maneval, J. Chandler, L. Bowen, K. L. Kaul, B. T. Helfand, C. H. Wang, M. Quinn, J Petkewicz, M. Paterakos, and V. Backman, “Nanocytological field carcinogenesis detection to mitigate overdiagnosis of prostate cancer: a proof of concept study,” PLoS One 10(2), e0115999 (2015).
29. L. Cherkezyan, Y. Stypula-Cyrus, H. Subramanian, C. White, M. Dela Cruz, R. K. Wali, M. J. Goldberg, L. K. Bianchi, H. K. Roy, and V. Backman, “Nanoscale changes in chromatin organization represent the initial steps of tumorigenesis: a transmission electron microscopy study,” BMC Cancer 14(1), 189 (2014).
30. V. J. Konda, L. Cherkezyan, H. Subramanian, K. Wroblewski, D. Damania, V. Becker, M. H. Gonzalez, A. Koons, M. Goldberg, M. K. Ferguson, I. Waxman, H. K. Roy, and V. Backman, “Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening,” Endoscopy 45(12), 983-988 (2013).
31. H. K. Roy, D. P. Damania, M. DelaCruz, D. P. Kunte, H. Subramanian, S. E. Crawford, A. K. Tiwari, R. K. Wali, and V. Backman, “Nano-architectural alterations in mucus layer fecal colonocytes in field carcinogenesis: potential for screening,” Cancer Prev. Res. (Phila.) 6(10), 1111-1119 (2013).
32. Y. Stypula-Cyrus, D. Damania, D. P. Kunte, M. D. Cruz, H. Subramanian, H. K. Roy, and V. Backman, “HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure,” PLoS One 8(5), e64600 (2013).
33. D. Damania, H. K. Roy, D. Kunte, J. A. Hurteau, H. Subramanian, L. Cherkezyan, N. Krosnjar, M. Shah, and V. Backman, “Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells,” Int. J. Cancer 133(5), 1143-1152 (2013).
34. D. Damania, H. K. Roy, H. Subramanian, D. S. Weinberg, D. K. Rex, M. J. Goldberg, J. Muldoon, L. Cherkezyan, Y. Zhu, L. K. Bianchi, D. Shah, P. Pradhan, M. Borkar, H. Lynch, and V. Backman, “Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization,” Cancer Res. 72(11), 2720-2727 (2012).
35. H. Subramanian, H. K. Roy, P. Pradhan, M. J. Goldberg, J. Muldoon, R. E. Brand, C. Sturgis, T. Hensing, D. Ray, A. Bogojevic, J. Mohammed, J. S. Chang, and V. Backman, “Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy,” Cancer Res. 69(13), 5357-5363 (2009).
36. D. Damania, H. Subramanian, A. K. Tiwari, Y. Stypula, D. Kunte, P. Pradhan, H. K. Roy, and V. Backman, “Role of Cytoskeleton in Controlling the Disorder Strength of Cellular Nanoscale Architecture,” Biophys. J. 99(3), 989-996 (2010).
37. L. Cherkezyan, I. Capoglu, H. Subramanian, J. D. Rogers, D. Damania, A. Taflove, and V. Backman, “Interferometric Spectroscopy of Scattered Light Can Quantify the Statistics of Subdiffractional Refractive-Index Fluctuations,” Phys. Rev. Lett. 111(3), 033903 (2013).
38. N. N. Boustany, S. A. Boppart, and V. Backman, “Microscopic Imaging and Spectroscopy with Scattered Light,” Annu. Rev. Biomed. Eng. 12(1), 285-314 (2010).
39. O. Graydon, N. Horiuchi, D. Pile, S. Pleasants, and R. Won, “Comex Media: Subtle Sensing,” Nat. Photonics 7(10), 763 (2013).
40. V. Konda, L. Cherkezyan, H. Subramanian, K. Wroblewski, D. Damania, V. Becker, M. Goldberg, J. Chennat, L. Karl, M. Ferguson, I. Waxman, H. Roy, and V. Backman, “Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening,” Endoscopy 45, 983-988 (2013).
41. X. Meng, Y. Zhang, L. Lao, R. Saito, A. Li, C. M. Bäckman, B. M. Berman, K. Ren, P. K. Wei, and R. X. Zhang, “Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model,” Pain 154(2), 294-305 (2013).
42. H. K. Roy, T. Hensing, and V. Backman, “Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification,” Future Oncol. 7(1), 1-3 (2011).
43. A. K. Tiwari, H. Subramanian, C. D. Maneval, R. K. Wali, V. Backman, and H. K. Roy, “Partial wave spectroscopic microscopy: a novel tool to assess perturbation in the cellular transcriptional activity during colon carcinogenesis,” Gastroenterology 144(5), S175 (2013).
44. H. G. Davies, M. H. F. Wilkins, J. Chayen, and L. F. La Cour, “The use of interference microscope to determine dry mass in living cells and as a quantitative cytochemical method,” Q. J. Microsc. Sci. 95, 271-304 (1954).
45. L. Cherkezyan, H. Subramanian, and V. Backman, “What structural length scales can be detected by the spectral variance of a microscope image?” Opt. Lett. 39(15), 4290-4293 (2014).
46. B. Deng, S. Melnik, and P. R. Cook, “Transcription factories, chromatin loops, and the dysregulation of gene expression in malignancy,” Semin. Cancer Biol. 23(2), 65-71 (2013).
47. K. Kumar, A. K. Abbas, J. C. Aster, and N. Fausto, Robbins & Cotran Pathologic Basis of Disease, 8th ed., Robbins Pathology (Saunders, 2009).
48. J. E. Chandler, H. Subramanian, C. D. Maneval, C. A. White, R. M. Levenson, and V. Backman, “High-speed spectral nanocytology for early cancer screening,” J. Biomed. Opt. 18(11), 117002 (2013).
49. D. Zhang, L. Cherkezyan, I. Capoglu, H. Subramanian, J. Chandler, S. Thompson, A. Taflove, and V. Backman, “Spectroscopic microscopy can quantify the statistics of subdiffractional refractive-index fluctuations in media with random rough surfaces,” Opt. Lett. 40(21), 4931-4934 (2015).
50. L. Cherkezyan, H. Subramanian, V. Stoyneva, J. D. Rogers, S. Yang, D. Damania, A. Taflove, and V. Backman, “Targeted alteration of real and imaginary refractive index of biological cells by histological staining,” Opt. Lett. 37(10), 1601-1603 (2012).
51. E. S. Cibas and B. S. Ducatman, Cytology: Diagnostic Principles and Clinical Correlates (W.B. Saunders, Philadelphia, 1996), pp. 14, 371.
52. H. K. Roy, H. Subramanian, D. Damania, T. A. Hensing, W. N. Rom, H. I. Pass, D. Ray, J. D. Rogers, A. Bogojevic, M. Shah, T. Kuzniar, P. Pradhan, and V. Backman, “Optical Detection of Buccal Epithelial Nanoarchitectural Alterations in Patients Harboring Lung Cancer: Implications for Screening,” Cancer Res. 70(20), 7748-7754 (2010).